Labcorp (LH)
Provides clinical diagnostics and global laboratory support for biopharma research.
Something off on this page? Send us feedback.
Sells routine and specialty diagnostics to healthcare providers, payers, employers, and patients, while providing central-laboratory and early-development services to biopharma customers. Most revenue comes from U.S. diagnostics, complemented by a global drug-development laboratory network.
Provides routine and specialty clinical testing through Diagnostics Laboratories, including anatomic pathology, genetics, genomics, toxicology, and consumer-initiated tests. Collection sites, specimen logistics, automated processing, and digital delivery serve physicians, health systems, payers, employers, and patients; nearly all segment revenue comes from the United States.
Supports drug development through Biopharma Laboratory Services. Its Central Laboratory and Early Development Research Laboratories businesses provide trial testing, kits, sample logistics and management, bioanalysis, and safety assessment for pharmaceutical, biotechnology, diagnostic, and contract-research customers across the United States, Europe, and Asia.
Links a broad test menu with collection access, laboratory automation, health-system partnerships, and global trial logistics. Revenue depends on testing volumes, biopharma research activity, payer contracts and reimbursement, and compliance with laboratory, billing, privacy, and drug-development regulations.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Truist Financial | Target | Target: $320 | Target: $365 |
| Sep 11, 2026 | UBS | Reiterate | Rating: —Target: $320 | Target: $380 |
| Sep 11, 2026 | Barclays | Reiterate | Rating: —Target: $320 | Target: $330 |
| Aug 10, 2026 | Mizuho Securities | Target | Target: $320 | Target: $355 |
| Jul 31, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $303 | Target: $338 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $141.8M · Total debt $6.77B · Total assets $18.53B · Shareholders' equity $8.61B
- Revenue
- $3.73B
- Operating income
- $451.6M
- Net income
- $298.7M
HistoryDividendAnnual yield
| Institutions | 97.53% | 79.97M shares | |
|---|---|---|---|
| 1,070 holders · as of Jun 30, 2026 | |||
| Insiders | 0.38% | 313.9K shares | |
| 24 holders · as of Aug 18, 2026 | |||
| Other | 2.09% | 1.71M shares | |
| remainder | |||
82.00M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.02% | 6.57M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.54% | 5.36M | as of Jun 30, 2026 |
Victory Capital Management IncInstitution | 5.90% | 4.84M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.77% | 3.91M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.49% | 3.68M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Kerrii B. Anderson | director | −3,000 | $318.02 |
| Aug 11, 2026 | Adam H. Schechter | director, officer: President & CEO | −4,669 | $320.37 |
| Aug 4, 2026 | Amy B. Summy | officer: EVP, Chief Marketing Officer | −924 | $306.74 |
| Aug 3, 2026 | Peter J. Wilkinson | officer: SVP, Chief Accounting Officer | −1,420 | $309.23 |
| Jul 2, 2026 | Bryan T. Vaughn | officer: EVP and President, Diagnostics | −234 | $286.19 |
- Quest Diagnostics
Closest national overlap in diagnostic information services
- Thermo Fisher Scientific
Pharma-services and PPD overlap in biopharma labs
- IQVIA
Global clinical research and central-lab overlap
- ICON
Central-lab and CRO overlap for trial sponsors
- NeoGenomics
Oncology diagnostics and pharma-services overlap
- Charles River Laboratories
Early-development and safety-assessment overlap
- Medpace
Smaller CRO central-lab overlap in clinical trials
- OPKO Health
Narrow BioReference overlap after asset sales
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Labcorp | $313.01 | −2.49% | $26.32B | 26.6 | 16.5 | 1.8 | +5.8% |
| Quest Diagnostics | $234.91 | −4.07% | $27.03B | 26.0 | 20.5 | 2.3 | +10.2% |
| Thermo Fisher Scientific | $659.56 | +0.12% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| IQVIA | $270.73 | +0.31% | $44.42B | 33.5 | 19.9 | 2.6 | +8.7% |
| ICON | $169.27 | −0.16% | $12.98B | 39.8 | 15.2 | 1.6 | +2.3% |
| NeoGenomics | $19.10 | −1.61% | $498.7M | — | 68.7 | 0.7 | +11.2% |
| Charles River Laboratories | $287.50 | +3.04% | $13.44B | — | 23.3 | 3.4 | −2.7% |
| Medpace | $628.20 | +0.64% | $17.42B | 36.6 | 34.1 | 6.3 | +17.2% |
| OPKO Health | $1.71 | +1.19% | $1.26B | — | — | 2.1 | +4.3% |
| Median | 35.4 | 23.3 | 2.5 | +9.5% |